M&A / Deals Cumberland to sell drug portfolio to Apotex for $100m Pharmaceutical Business ReviewUnder the agreement, Apotex will acquire Cumberland's branded medicines for cash, subject to approval by Cumberland's shareholders.M&A / DealsRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) Pharmaceutical Business Review Under the agreement, Apotex will acquire Cumberland’s branded medicines for cash, subject to approval by Cumberland’s shareholders. M&A / DealsRead full story Post navigation Previous: FDA clears first genetic hearing loss gene therapyNext: Regeneron cuts White House pricing deal, offers new gene therapy for free Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026